Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 30;14(6):1101-1111.
doi: 10.21037/gs-2025-84. Epub 2025 Jun 26.

Postmastectomy radiotherapy indications using pathological prognostic staging in node-positive breast cancer

Juan Zhou #  1 , Lin-Feng Guo #  2 , San-Gang Wu  2 , Zhen-Yu He  3
Affiliations

Postmastectomy radiotherapy indications using pathological prognostic staging in node-positive breast cancer

Juan Zhou et al. Gland Surg. .

Abstract

Background: The role of pathological prognostic staging (PPS) on postmastectomy radiotherapy (PMRT) selection remains unclear. This study aimed to investigate the impact of PPS on PMRT selection in patients with node-positive breast cancer (BC).

Methods: We included women diagnosed with BC between 2010 and 2015 from the Surveillance, Epidemiology, and End Results database. Chi-square test, operating characteristic curve, and competing-risks analyses with the Fine and Gray model were used for statistical analyses.

Results: A total of 14,830 patients were included. Overall, 8,807 (59.4%) patients received PMRT while 6,023 (40.6%) did not. Among them, 11,767 patients (79.3%) had their stage changed, with 1,086 (7.3%) upstaged and 10,681 (72.0%) downstaged. PPS had better prognostic accuracy compared with anatomical staging (AS) (P<0.001). Regarding PPS, PMRT significantly decreased 5-year breast cancer-specific mortality in patients with stage IIIA (14.4% vs. 19.7%, P<0.001), IIIB (19.8% vs. 27.2%, P=0.003), and IIIC (38.5% vs. 45.7%, P=0.049) diseases compared with those of other stages. However, no significant effects were observed in stage IA, IB, IIA, and IIB diseases.

Conclusions: Our study highlights significant staging differences between AS and PPS in patients with node-positive BC. The high rate of downstaging observed with PPS suggests its potential to enhance risk stratification and optimize treatment strategies, especially in guiding the appropriate use of PMRT.

Keywords: Breast cancer (BC); mastectomy; radiotherapy; staging; survival.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-2025-84/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Receiver operating characteristic analyses for comparing the prognostic abilities between the AS and PPS. AS, anatomical staging; AUC, area under the curve; PPS, pathological prognostic staging; ROC, receiver operating characteristic.
Figure 2
Figure 2
The cumulative incidence of breast cancer-specific mortality curves of the anatomical staging (A) and pathological prognostic staging (B) using competing-risks regression.
Figure 3
Figure 3
The effect of PMRT on breast cancer-specific mortality according to the breast cancer subtypes: (A) HoR+/HER2−; (B) HoR+/HER2+; (C) HoR−/HER2+; (D) HoR−/HER2−. HER2, human epidermal growth factor receptor 2; HoR, hormone receptor; PMRT, postmastectomy radiotherapy.
Figure 4
Figure 4
The effect of PMRT on breast cancer-specific mortality according to the anatomical staging. (A) IIA; (B) IIB; (C) IIIA; (D) IIIB; (E) IIIC. PMRT, postmastectomy radiotherapy.
Figure 5
Figure 5
The effect of PMRT on breast cancer-specific mortality according to the pathological prognostic staging. (A) IA; (B) IB; (C) IIA; (D) IIB; (E) IIIA; (F) IIIB; (G) IIIC. PMRT, postmastectomy radiotherapy.
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63. 10.3322/caac.21834 - DOI - PubMed
    1. Wang J, Wu SG. Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives. Breast Cancer (Dove Med Press) 2023;15:721-30. 10.2147/BCTT.S432526 - DOI - PMC - PubMed
    1. Lei JT, Jaehnig EJ, Smith H, et al. The Breast Cancer Proteome and Precision Oncology. Cold Spring Harb Perspect Med 2023;13:a041323. 10.1101/cshperspect.a041323 - DOI - PMC - PubMed
    1. National Comprehensive Cancer Network. (NCCN) clinical practice guidelines in Oncology. Breast Cancer 2024. Version 1. Available online: https://www.nccn.org/professionals/physician_gls/pdf/breastl.pdf
    1. Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2024;35:159-82. 10.1016/j.annonc.2023.11.016 - DOI - PubMed